15 results
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
as are developing SLRN-517 in chronic urticaria.
The following chart summarizes the status of our current pipeline:
(1)Phase 2b/3 trial in Uveitis.
(2 … indication of interest for SLRN-517 is chronic urticaria.
Table of Contents
Leadership
Our company is led by Shao-Lee Lin, M.D., Ph.D., our Founder
8-K
EX-99.2
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
) is a chronic Inflammatory skin disease causing scarring, abscesses, malodor and pain. HS typically occurs in areas with high concentrations of sweat
8-K
EX-99.3
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
DactylitisEnthesitis Spondylitis Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations including … resolution of disease symptoms remain an unmet need for patients Hidradenitis Suppurativa (HS) is a chronic Inflammatory disease characterized by skin
8-K
EX-99.1
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
visit www.clinicaltrials.gov.
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized
8-K
EX-99.1
klh7k8 mo
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
EX-99.1
rr4abtth
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
10-Q
3kjt39m
15 Jun 23
Quarterly report
4:19pm
424B4
yhyhw j90lkb
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
4cwiyevnojl86jnzeqrk
1 May 23
IPO registration (amended)
6:10am
S-1
EX-23.5
susgca8ah rbuzi40c
13 Apr 23
IPO registration
5:10pm
S-1
ksbjxind4mtzlr
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next